and Company have broadened their commercial agreement under which the former will be the sole distributor and promoter of the migraine medication Emgality (galcanezumab) in 11 new markets. The expanded territories are Canada, Colombia, Israel, Kuwait, Mexico, Qatar, Saudi Arabia, South Korea, Taiwan, Turkey and the United Arab Emirates. The gold standard of business intelligence.
The financial terms of the deal include an upfront payment of $22.5m to Lilly, accompanied by additional sales-based milestone payments. The deal builds on Organon’s existing distribution responsibilities for the asset in Europe since February 2024.
Organon CEO Kevin Ali stated: “The broadening of this agreement is a testament to Organon’s best-in-class commercialisation capabilities, global footprint and deep expertise in women’s health. “We know that migraine ranks as the leading cause of disability among young women and we’re proud to expand our offering to more women and men around the world living with episodic or chronic migraine.” Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form A humanised monoclonal antibody, Emgality acts as a calcitonin g.